HCC
TCRT icon

Hirtle Callaghan & Co’s Alaunos Therapeutics TCRT Stock Holding History

Hirtle Callaghan & Co’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-22
Closed -$16K – 324
2014
Q4 		$16K Hold
22
– – ﹤0.01% 399
2014
Q3 		$9K Hold
22
– – ﹤0.01% 468
2014
Q2 		$13K Buy
+22
New +$12.2K ﹤0.01% 488
2014
Q1 		– Sell
-22
Closed -$14K – 665
2013
Q4 		$14K Buy
22
+14
+175% +$8.34K ﹤0.01% 449
2013
Q3 		$5K Hold
8
– – ﹤0.01% 515
2013
Q2 		$3K Buy
+8
New +$2.22K 0.03% 57

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hirtle Callaghan & Co's TCRT Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Alaunos Therapeutics (TCRT) in Q1 2015, closing a stake of 22 shares — an estimated $16K sold.

Hirtle Callaghan & Co first reported a position in TCRT in Q2 2013 and held it in 6 quarters. The position peaked at $16K in Q4 2014. 128 funds tracked by Wall St. Rank hold TCRT as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining Alaunos Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 22 Alaunos Therapeutics shares in Q1 2015, an estimated $16K.
  • Hirtle Callaghan & Co first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 6 quarters.
  • Hirtle Callaghan & Co's Alaunos Therapeutics position peaked at $16K in Q4 2014.
  • 128 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.